HRP20100490T1 - Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore - Google Patents
Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore Download PDFInfo
- Publication number
- HRP20100490T1 HRP20100490T1 HR20100490T HRP20100490T HRP20100490T1 HR P20100490 T1 HRP20100490 T1 HR P20100490T1 HR 20100490 T HR20100490 T HR 20100490T HR P20100490 T HRP20100490 T HR P20100490T HR P20100490 T1 HRP20100490 T1 HR P20100490T1
- Authority
- HR
- Croatia
- Prior art keywords
- pde4 inhibitor
- combination
- receptor antagonist
- combination according
- simultaneous
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title claims abstract 13
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims abstract 13
- 239000003149 muscarinic antagonist Substances 0.000 title claims 8
- 239000002253 acid Substances 0.000 claims abstract 4
- 150000001450 anions Chemical class 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000005557 antagonist Substances 0.000 claims abstract 3
- ZLLPOXZGRDWOKF-LBFFRULKSA-N [(3R)-1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9H-xanthene-9-carboxylate Chemical compound C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12C(C)C1=CC=CC=C1 ZLLPOXZGRDWOKF-LBFFRULKSA-N 0.000 claims abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 101150015280 Cel gene Proteins 0.000 claims 3
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 claims 3
- 229950001653 cilomilast Drugs 0.000 claims 3
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 3
- 229960002586 roflumilast Drugs 0.000 claims 3
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 claims 2
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229950002896 tetomilast Drugs 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 claims 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 claims 1
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 claims 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- -1 compound (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2 ]octane bromide Chemical class 0.000 claims 1
- PCCPERGCFKIYIS-AWEZNQCLSA-N daxalipram Chemical compound C1=C(OC)C(OCCC)=CC([C@@]2(C)OC(=O)NC2)=C1 PCCPERGCFKIYIS-AWEZNQCLSA-N 0.000 claims 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- STTRYQAGHGJXJJ-LICLKQGHSA-N filaminast Chemical compound COC1=CC=C(C(\C)=N\OC(N)=O)C=C1OC1CCCC1 STTRYQAGHGJXJJ-LICLKQGHSA-N 0.000 claims 1
- 229950006884 filaminast Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229950008462 lirimilast Drugs 0.000 claims 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 claims 1
- 229950005184 piclamilast Drugs 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229950003899 tofimilast Drugs 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Kombinacija, naznačena time, da sadrži (a) inhibitor PDE4 i (b) antagonist muskarinskih receptora M3, koji antagonist je spoj (3R)-1-fenetil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo[2.2.2]oktan, u obliku soli koja sadrži anion X, koji je farmaceutski prihvatljiv anion mono ili polivalentne kiseline. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Kombinacija, naznačena time, da sadrži (a) inhibitor PDE4 i (b) antagonist muskarinskih receptora M3, koji antagonist je spoj (3R)-1-fenetil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo[2.2.2]oktan, u obliku soli koja sadrži anion X, koji je farmaceutski prihvatljiv anion mono ili polivalentne kiseline.
2. Kombinacija u skladu s patentnim zahtjevom 1, naznačena time, da je antagonist M3 muskarinskih receptora (b) spoj (3R)-1-fenetil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo [2.2.2]oktan bromid.
3. Kombinacija u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine teofilin, drotaverin hidroklorid, cilomilast, roflumilast, denbufilin, rolipram, tetomilast, enprofilin, arofilin, cipamfilin, tofimilast, filaminast, piklamilast, (R)-(+)-4-[2-(3-ciklopentiloksi-4-metoksifenil)-2-feniletil]piridin, mesopram, N-(3,5-diklor-4-piridinil)-2-[1-(4-fluorobenzil)-5-hidroksi-1H-indol-3-il]-2-oksoacetamid, CDC-801 (ex. Celgene), CC-1088 (ex. Celgene), Lirimilast, ONO-6126 (ex. Ono), CC-10004 (ex. Celgene) i MN-001 (ex. Kvorin), po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
4. Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog, te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
5. Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je inhibitor PDE4 roflumilast.
6. Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je inhibitor PDE4 cilomilast.
7. Kombinacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da su djelatne tvari (a) i (b) sadržane u jednom farmaceutskom pripravku.
8. Kombinacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da dodatno sadržava (c) dodatni djelatni spoj koji je odabran između: (a) β2-agonista, (b) kortikosteroida, (c) antagonista leukotrien-D4 receptora, (d) inhibitora egfr-kinaze, (e) inhibitora p38 kinaze i (f) agonista NK1 receptora.
9. Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) β2-agonisti i (b) kortikosteroidi.
10. Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonista muskarinskih receptora M3 kako se definiraju u patentnom zahtjevu 1 ili 2, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesti dišnih putova koja reagira na M3 antagonizam kod bolesnika.
11. Uporaba u skladu s patentnim zahtjevom 10, naznačena time, da je bolest dišnih putova astma ili kronična opstruktivna bolest pluća (COPD).
12. Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
13. Proizvedeni lijek u skladu s patentnim zahtjevom 12, naznačen time, da dodatno sadržava djelatni spoj (c) kako se definira u patentnom zahtjevu 8 ili 9.
14. Komplet dijelova, naznačen time, da sadrži (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (a) inhibitorom PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za liječenje bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
15. Komplet u skladu s patentnim zahtjevom 14, naznačen time, da dodatno sadrži djelatni spoj (c) kako se definira u patentnom zahtjevu 8 ili 9.
16. Pakiranje, naznačeno time, da sadrži (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 i (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
17. Pakiranje u skladu s patentnim zahtjevom 16, naznačeno time, da dodatno sadrži djelatni spoj (c) kako se definira u patentnom zahtjevu 8 ili 9.
18. Uporaba (b) antagonista muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (a) inhibitorom PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
19. Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401312A ES2257152B1 (es) | 2004-05-31 | 2004-05-31 | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP2005001969 | 2005-02-24 | ||
| GB2005000740 | 2005-02-25 | ||
| GB2005000722 | 2005-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100490T1 true HRP20100490T1 (hr) | 2010-10-31 |
Family
ID=34968792
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090106T HRP20090106T3 (hr) | 2004-05-31 | 2009-02-20 | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergičke agoniste |
| HR20100104T HRP20100104T1 (hr) | 2004-05-31 | 2010-02-26 | Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide |
| HR20100490T HRP20100490T1 (hr) | 2004-05-31 | 2010-09-03 | Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090106T HRP20090106T3 (hr) | 2004-05-31 | 2009-02-20 | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergičke agoniste |
| HR20100104T HRP20100104T1 (hr) | 2004-05-31 | 2010-02-26 | Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20110224177A1 (hr) |
| EP (5) | EP1905451B1 (hr) |
| JP (1) | JP2012211183A (hr) |
| AT (3) | ATE454904T1 (hr) |
| AU (3) | AU2005247105B2 (hr) |
| CA (3) | CA2568568C (hr) |
| CY (1) | CY1110829T1 (hr) |
| DE (3) | DE602005012102D1 (hr) |
| DK (2) | DK1905451T3 (hr) |
| ES (2) | ES2317245T3 (hr) |
| HK (1) | HK1096605A1 (hr) |
| HR (3) | HRP20090106T3 (hr) |
| IL (3) | IL179686A0 (hr) |
| MX (3) | MXPA06013850A (hr) |
| NZ (3) | NZ551670A (hr) |
| PL (2) | PL1891974T3 (hr) |
| PT (3) | PT1905451E (hr) |
| RS (3) | RS50786B (hr) |
| RU (3) | RU2385156C2 (hr) |
| SI (3) | SI1891974T1 (hr) |
| WO (3) | WO2005115463A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20100150884A1 (en) * | 2005-02-10 | 2010-06-17 | Oncolys Biopharma Inc. | Anticancer Agent to Be Combined with Telomelysin |
| WO2008102128A2 (en) * | 2007-02-19 | 2008-08-28 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| GB0814728D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
| EP4403231A2 (en) | 2009-02-26 | 2024-07-24 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| CN107964016B (zh) | 2009-05-14 | 2021-10-01 | 天津合美医药科技有限公司 | 噻吩衍生物 |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| RU2666963C2 (ru) | 2012-04-13 | 2018-09-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Агрегированные частицы |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| RS57075B1 (sr) * | 2013-03-15 | 2018-06-29 | Verona Pharma Plc | Kombinacija leka |
| GB201308933D0 (en) * | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
| CN110592082A (zh) * | 2013-07-05 | 2019-12-20 | 柏业公司 | 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构及其用途 |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| DK0503031T3 (da) | 1990-09-26 | 1999-01-04 | Pharmachemie Bv | Inhalator med et reservoir til flere doser af et materiale, der skal inhaleres |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| JP2924924B2 (ja) | 1992-12-18 | 1999-07-26 | シェリング・コーポレーション | 粉末薬物のための吸入器 |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| CN1142798C (zh) | 1995-04-14 | 2004-03-24 | 葛兰素惠尔康公司 | 沙美特罗的计定剂量吸入器 |
| DK0837710T3 (da) | 1995-06-21 | 2002-04-02 | Sofotec Gmbh & Co Kg | Lægemiddelpulverpatron med integreret doseringsindretning og inhalator for lægemidler på pulverform |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
| JP2004509159A (ja) * | 2000-09-22 | 2004-03-25 | グラクソ グループ リミテッド | 新規なアルカン酸誘導体 |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| CA2733294C (en) | 2000-10-31 | 2011-12-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical combination of a tiotropium salt and ciclesonide |
| DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
| ATE334128T1 (de) * | 2000-12-28 | 2006-08-15 | Almirall Prodesfarma Ag | Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten |
| AU2002314102A1 (en) * | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| PT1610787E (pt) * | 2003-03-28 | 2008-04-23 | Nycomed Gmbh | Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias |
| MXPA05010161A (es) * | 2003-03-28 | 2005-11-16 | Altana Pharma Ag | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
-
2005
- 2005-05-31 AU AU2005247105A patent/AU2005247105B2/en not_active Ceased
- 2005-05-31 DE DE602005012102T patent/DE602005012102D1/de active Active
- 2005-05-31 ES ES05748688T patent/ES2317245T3/es active Active
- 2005-05-31 EP EP07023760A patent/EP1905451B1/en active Active
- 2005-05-31 SI SI200531128T patent/SI1891974T1/sl unknown
- 2005-05-31 AU AU2005247104A patent/AU2005247104B2/en not_active Ceased
- 2005-05-31 MX MXPA06013850A patent/MXPA06013850A/es active IP Right Grant
- 2005-05-31 AT AT07023760T patent/ATE454904T1/de active
- 2005-05-31 AT AT07019646T patent/ATE474601T1/de active
- 2005-05-31 WO PCT/EP2005/005837 patent/WO2005115463A1/en active Application Filing
- 2005-05-31 MX MXPA06013846A patent/MXPA06013846A/es active IP Right Grant
- 2005-05-31 RU RU2006146813/15A patent/RU2385156C2/ru not_active IP Right Cessation
- 2005-05-31 SI SI200530959T patent/SI1905451T1/sl unknown
- 2005-05-31 PT PT07023760T patent/PT1905451E/pt unknown
- 2005-05-31 NZ NZ551670A patent/NZ551670A/en not_active IP Right Cessation
- 2005-05-31 RU RU2006146673/15A patent/RU2379033C2/ru not_active IP Right Cessation
- 2005-05-31 WO PCT/EP2005/005839 patent/WO2005115465A1/en not_active Application Discontinuation
- 2005-05-31 AU AU2005247106A patent/AU2005247106B2/en not_active Ceased
- 2005-05-31 NZ NZ551666A patent/NZ551666A/en not_active IP Right Cessation
- 2005-05-31 EP EP10003385A patent/EP2210614A1/en not_active Withdrawn
- 2005-05-31 DK DK07023760.7T patent/DK1905451T3/da active
- 2005-05-31 ES ES07023760T patent/ES2336144T3/es active Active
- 2005-05-31 RS RSP-2009/0075A patent/RS50786B/sr unknown
- 2005-05-31 EP EP05746222A patent/EP1761279A1/en not_active Withdrawn
- 2005-05-31 EP EP07019646A patent/EP1891974B1/en active Active
- 2005-05-31 RS RSP-2010/0104A patent/RS51206B/sr unknown
- 2005-05-31 AT AT05748688T patent/ATE419011T1/de active
- 2005-05-31 NZ NZ551669A patent/NZ551669A/en not_active IP Right Cessation
- 2005-05-31 CA CA2568568A patent/CA2568568C/en not_active Expired - Fee Related
- 2005-05-31 DK DK07019646.4T patent/DK1891974T3/da active
- 2005-05-31 DE DE602005018969T patent/DE602005018969D1/de active Active
- 2005-05-31 SI SI200530599T patent/SI1765404T1/sl unknown
- 2005-05-31 RS RSP-2010/0379A patent/RS51422B/en unknown
- 2005-05-31 MX MXPA06013849A patent/MXPA06013849A/es active IP Right Grant
- 2005-05-31 EP EP05759006A patent/EP1765405A1/en not_active Withdrawn
- 2005-05-31 DE DE602005022499T patent/DE602005022499D1/de active Active
- 2005-05-31 CA CA2569074A patent/CA2569074C/en not_active Expired - Fee Related
- 2005-05-31 PT PT05748688T patent/PT1765404E/pt unknown
- 2005-05-31 PT PT07019646T patent/PT1891974E/pt unknown
- 2005-05-31 PL PL07019646T patent/PL1891974T3/pl unknown
- 2005-05-31 RU RU2006147269/15A patent/RU2404772C2/ru not_active IP Right Cessation
- 2005-05-31 PL PL07023760T patent/PL1905451T3/pl unknown
- 2005-05-31 WO PCT/EP2005/005838 patent/WO2005115464A1/en not_active Application Discontinuation
- 2005-05-31 CA CA2568571A patent/CA2568571C/en not_active Expired - Fee Related
-
2006
- 2006-11-29 IL IL179686A patent/IL179686A0/en unknown
- 2006-11-29 IL IL179690A patent/IL179690A/en not_active IP Right Cessation
- 2006-11-29 IL IL179685A patent/IL179685A/en not_active IP Right Cessation
-
2007
- 2007-04-03 HK HK07103580.3A patent/HK1096605A1/xx not_active IP Right Cessation
-
2009
- 2009-02-20 HR HR20090106T patent/HRP20090106T3/hr unknown
-
2010
- 2010-02-26 HR HR20100104T patent/HRP20100104T1/hr unknown
- 2010-09-03 HR HR20100490T patent/HRP20100490T1/hr unknown
- 2010-10-11 CY CY20101100905T patent/CY1110829T1/el unknown
-
2011
- 2011-03-14 US US13/047,039 patent/US20110224177A1/en not_active Abandoned
-
2012
- 2012-07-06 JP JP2012152730A patent/JP2012211183A/ja active Pending
- 2012-09-05 US US13/603,985 patent/US20130196961A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100490T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore | |
| HRP20100489T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore | |
| JP2008500986A5 (hr) | ||
| DK2265257T3 (en) | Indhaleringssammensætning containing aclidinium for the treatment of chronic obstructive pulmonary disease | |
| SI2928889T1 (en) | COMPOUNDS WITH ACTIVITY OF ANTAGONIST OF MUSCARIN RECEPTORS AND BETA2 AGENTIST ADRENERGY RECEPTORS | |
| JP2007524699A5 (hr) | ||
| ES2610104T3 (es) | Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias | |
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| RU2011105460A (ru) | Фармацевтический продукт, содержащий антагонист мускаринового рецептора и второй активный ингредиент | |
| WO2006117534A2 (en) | New use | |
| KR20070017543A (ko) | 항무스카린제 및 ｐｄｅ4 저해제를 포함하는 조합물 | |
| KR20070017542A (ko) | 항무스카린제 및 ｐｄｅ4 저해제를 포함하는 조합물 | |
| KR20070018104A (ko) | 항무스카린제 및 베타-아드레날린 작용제를 포함하는조합물 |